BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8688984)

  • 1. Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability.
    Barber BL; Santanello NC
    Int J Clin Pharmacol Ther; 1995 Nov; 33(11):598-604. PubMed ID: 8688984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life.
    Strohmaier K; Snyder E; Adamsons I
    J Am Optom Assoc; 1998 Jul; 69(7):441-51. PubMed ID: 9697378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group.
    Sverrisson T; Gross R; Pearson J; Rusk C; Adamsons I
    J Glaucoma; 1999 Oct; 8(5):315-24. PubMed ID: 10529932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.
    Adamsons IA; Polis A; Ostrov CS; Boyle JE
    J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy.
    Sonty S; Henry JC; Sharpe ED; Weiss MJ; Stewart JA; Nelson LA; Stewart WC
    Acta Ophthalmol; 2008 Jun; 86(4):419-23. PubMed ID: 18039347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
    Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
    Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
    Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a questionnaire for comparing the tolerability of ophthalmic medications.
    Barber BL; Strahlman ER; Laibovitz R; Guess HA; Reines SA
    Ophthalmology; 1997 Feb; 104(2):334-42. PubMed ID: 9052642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.
    Chiseliţă D; Antohi I; Medvichi R; Danielescu C
    Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Jenkins JN
    Eye (Lond); 2004 Sep; 18(9):905-10. PubMed ID: 15002017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients].
    Kałuzny JJ; Szaflik J; Czechowicz-Janicka K; Kałuzny J; Orzałkiewicz A; Zaleska-Zmijewska A; Krajewska M; Stewart JA; Leech JN; Stewart WC
    Klin Oczna; 2004; 106(1-2 Suppl):241-2. PubMed ID: 15510513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
    Nesher R; Ticho U
    Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension.
    Suzuki ER; Franklin LM; da Silva LJ; Figueiredo CR; Netto JA; Batista WD
    Curr Med Res Opin; 2006 Sep; 22(9):1799-805. PubMed ID: 16968583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.